Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial
- PMID: 16478899
- DOI: 10.1001/jama.295.7.761
Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial
Erratum in
- JAMA. 2006 Mar 15;295(11):1252
Abstract
Context: Rimonabant, a selective cannabinoid-1 receptor blocker, may reduce body weight and improve cardiometabolic risk factors in patients who are overweight or obese.
Objective: To compare the efficacy and safety of rimonabant with placebo each in conjunction with diet and exercise for sustained changes in weight and cardiometabolic risk factors over 2 years.
Design, setting, and participants: Randomized, double-blind, placebo-controlled trial of 3045 obese (body mass index > or =30) or overweight (body mass index >27 and treated or untreated hypertension or dyslipidemia) adult patients at 64 US and 8 Canadian clinical research centers from August 2001 to April 2004.
Intervention: After a 4-week single-blind placebo plus diet (600 kcal/d deficit) run-in period, patients were randomized to receive placebo, 5 mg/d of rimonabant, or 20 mg/d of rimonabant for 1 year. Rimonabant-treated patients were rerandomized to receive placebo or continued to receive the same rimonabant dose while the placebo group continued to receive placebo during year 2.
Main outcome measures: Body weight change over year 1 and prevention of weight regain during year 2. Additional efficacy measures included changes in waist circumference, plasma lipid levels, and other cardiometabolic risk factors.
Results: At year 1, the completion rate was 309 (51%) patients in the placebo group, 620 (51%) patients in the 5 mg of rimonabant group, and 673 (55%) patients in the 20 mg of rimonabant group. Compared with the placebo group, the 20 mg of rimonabant group produced greater mean (SEM) reductions in weight (-6.3 [0.2] kg vs -1.6 [0.2] kg; P<.001), waist circumference (-6.1 [0.2] cm vs -2.5 [0.3] cm; P<.001), and level of triglycerides (percentage change, -5.3 [1.2] vs 7.9 [2.0]; P<.001) and a greater increase in level of high-density lipoprotein cholesterol (percentage change, 12.6 [0.5] vs 5.4 [0.7]; P<.001). Patients who were switched from the 20 mg of rimonabant group to the placebo group during year 2 experienced weight regain while those who continued to receive 20 mg of rimonabant maintained their weight loss and favorable changes in cardiometabolic risk factors. Use of different imputation methods to account for the high rate of dropouts in all 3 groups yielded similar results. Rimonabant was generally well tolerated; the most common drug-related adverse event was nausea (11.2% for the 20 mg of rimonabant group vs 5.8% for the placebo group).
Conclusions: In this multicenter trial, treatment with 20 mg/d of rimonabant plus diet for 2 years promoted modest but sustained reductions in weight and waist circumference and favorable changes in cardiometabolic risk factors. However, the trial was limited by a high drop-out rate and longer-term effects of the drug require further study. Clinical Trials Registration ClinicalTrials.gov Identifier: NCT00029861.
Comment in
-
Obesity research--limitations of methods, measurements, and medications.JAMA. 2006 Feb 15;295(7):826-8. doi: 10.1001/jama.295.7.826. JAMA. 2006. PMID: 16478906 No abstract available.
-
Is rimonabant a safe and effective therapy for sustained weight loss and improved cardiometabolic risk factors?Nat Clin Pract Cardiovasc Med. 2006 Jul;3(7):364-5. doi: 10.1038/ncpcardio0598. Nat Clin Pract Cardiovasc Med. 2006. PMID: 16810170 No abstract available.
-
Effect of rimonabant on weight and cardiometabolic risk factors.JAMA. 2006 Aug 9;296(6):649-50; author reply 650-1. doi: 10.1001/jama.296.6.649. JAMA. 2006. PMID: 16896103 No abstract available.
-
Obesity. Rimonabant trials confirm benefit.Rev Cardiovasc Med. 2006 Spring;7(2):102-6. Rev Cardiovasc Med. 2006. PMID: 16915128 No abstract available.
-
Rimonabant--a new weapon in the war on obesity.Curr Hypertens Rep. 2006 Dec;8(6):441-2. doi: 10.1007/s11906-006-0019-6. Curr Hypertens Rep. 2006. PMID: 17087852 No abstract available.
Similar articles
-
[Pharmacological therapy of obesity].G Ital Cardiol (Rome). 2008 Apr;9(4 Suppl 1):83S-93S. G Ital Cardiol (Rome). 2008. PMID: 18773755 Italian.
-
Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program.Diabetes Care. 2008 Feb;31 Suppl 2:S229-40. doi: 10.2337/dc08-s258. Diabetes Care. 2008. PMID: 18227491
-
Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study.Eur Heart J. 2008 Jul;29(14):1761-71. doi: 10.1093/eurheartj/ehn076. Epub 2008 Apr 15. Eur Heart J. 2008. PMID: 18417461 Clinical Trial.
-
[Rimonabant improves cardiometabolic risk profile in obese or overweight subjects: overview of RIO studies].Rev Med Suisse. 2006 Aug 23;2(76):1916-23. Rev Med Suisse. 2006. PMID: 16972542 Review. French.
-
CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant.J Neuroendocrinol. 2008 May;20 Suppl 1:139-46. doi: 10.1111/j.1365-2826.2008.01681.x. J Neuroendocrinol. 2008. PMID: 18426513 Review.
Cited by
-
Does rimonabant independently affect free fatty acid and glucose metabolism?J Clin Endocrinol Metab. 2012 Mar;97(3):819-27. doi: 10.1210/jc.2011-2486. Epub 2011 Dec 14. J Clin Endocrinol Metab. 2012. PMID: 22170727 Free PMC article. Clinical Trial.
-
Anti-obesity drugs: past, present and future.Dis Model Mech. 2012 Sep;5(5):621-6. doi: 10.1242/dmm.009621. Dis Model Mech. 2012. PMID: 22915024 Free PMC article. Review.
-
Metabolic syndrome and chronic kidney disease.Indian J Nephrol. 2008 Jan;18(1):1-4. doi: 10.4103/0971-4065.41279. Indian J Nephrol. 2008. PMID: 20368911 Free PMC article.
-
Activation of the endocannabinoid system mediates cardiac hypertrophy induced by rosiglitazone.Acta Pharmacol Sin. 2022 Sep;43(9):2302-2312. doi: 10.1038/s41401-022-00858-x. Epub 2022 Feb 21. Acta Pharmacol Sin. 2022. PMID: 35190698 Free PMC article.
-
The Endocannabinoid System as a Therapeutic Target in Diabetic Peripheral Neuropathic Pain: A Review.J Microsc Ultrastruct. 2021 May 24;10(2):47-54. doi: 10.4103/jmau.jmau_97_20. eCollection 2022 Apr-Jun. J Microsc Ultrastruct. 2021. PMID: 35832317 Free PMC article. Review.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous